Cellular models of alpha‐synuclein toxicity and aggregation
M Delenclos, JD Burgess… - Journal of …, 2019 - Wiley Online Library
Misfolding and aggregation of alpha‐synuclein (α‐synuclein) with concomitant cytotoxicity is
a hallmark of Lewy body related disorders such as Parkinson's disease, dementia with Lewy …
a hallmark of Lewy body related disorders such as Parkinson's disease, dementia with Lewy …
Cellular models to investigate biochemical pathways in Parkinson's disease
Cellular models are instrumental in dissecting a complex pathological process into simpler
molecular events. Parkinson's disease is multifactorial and clinically heterogeneous; the …
molecular events. Parkinson's disease is multifactorial and clinically heterogeneous; the …
[HTML][HTML] LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress
Studies of Parkinson's disease (PD) have been hindered by lack of access to affected
human dopaminergic (DA) neurons. Here, we report generation of induced pluripotent stem …
human dopaminergic (DA) neurons. Here, we report generation of induced pluripotent stem …
Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease
Parkinson's disease (PD) is a debilitating neurodegenerative condition characterized by the
loss of dopaminergic neurons in substantia nigra. MPP+ as a dopaminergic neurotoxin …
loss of dopaminergic neurons in substantia nigra. MPP+ as a dopaminergic neurotoxin …
[HTML][HTML] Cell-based assays for Parkinson's disease using differentiated human LUHMES cells
X Zhang, M Yin, M Zhang - Acta Pharmacologica Sinica, 2014 - nature.com
Aim: Lund human mesencephalic (LUHMES) cells can be differentiated to post-mitotic cells
with biochemical, morphological and functional features of dopaminergic (DAergic) neurons …
with biochemical, morphological and functional features of dopaminergic (DAergic) neurons …
Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease
DF Lázaro, MAS Pavlou, TF Outeiro - Experimental neurology, 2017 - Elsevier
Neurodegenerative diseases are highly debilitating conditions characterised primarily by
progressive neuronal loss and impairment of the nervous system. Parkinson's disease (PD) …
progressive neuronal loss and impairment of the nervous system. Parkinson's disease (PD) …
Classic and evolving animal models in Parkinson's disease
Parkinson's disease (PD) is a progressive neurodegenerative disease with motor and non-
motor symptoms. PD is characterized by the degeneration of dopaminergic neurons in the …
motor symptoms. PD is characterized by the degeneration of dopaminergic neurons in the …
[HTML][HTML] Modeling Parkinson's disease using induced pluripotent stem cells
B Byers, H Lee, R Reijo Pera - Current neurology and neuroscience …, 2012 - Springer
Our understanding of the underlying molecular mechanism of Parkinson's disease (PD) is
hampered by a lack of access to affected human dopaminergic (DA) neurons on which to …
hampered by a lack of access to affected human dopaminergic (DA) neurons on which to …
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease
BR Pinho, SD Reis, P Guedes-Dias… - Pharmacological …, 2016 - Elsevier
Histone deacetylases (HDACs) are key epigenetic enzymes and emerging drug targets in
cancer and neurodegeneration. Pan-HDAC inhibitors provided neuroprotection in …
cancer and neurodegeneration. Pan-HDAC inhibitors provided neuroprotection in …
RA differentiation enhances dopaminergic features, changes redox parameters, and increases dopamine transporter dependency in 6-hydroxydopamine-induced …
FM Lopes, LL da Motta, MA De Bastiani… - Neurotoxicity …, 2017 - Springer
Research on Parkinson's disease (PD) and drug development is hampered by the lack of
suitable human in vitro models that simply and accurately recreate the disease conditions …
suitable human in vitro models that simply and accurately recreate the disease conditions …